Alzheon, Inc. Overview
Pro stress-test →Alzheon is an American clinical-stage biopharmaceutical company based in Framingham, Massachusetts, developing medicines for patients with Alzheimer's disease and other neurological and psychiatric disorders. The company's lead candidate, ALZ-801, is an oral, brain-penetrant drug designed to prevent amyloid oligomer formation, slow disease progression, and preserve cognition.
Strategic Profile
Pro stress-test →The company aims to provide safe, effective, and accessible therapies that address the underlying causes of Alzheimer's and other neurodegenerative diseases, with a focus on precision medicine approaches targeting high-risk genetic populations such as APOE4/4 homozygotes. Alzheon has launched Phase 3 studies of an Alzheimer's medicine designed to block the formation of toxic clusters in the brain known as amyloid oligomers, which damage neurons in Alzheimer's patients.
Competitive Landscape
Pro stress-test →Alzheon competes in the Alzheimer's disease therapeutics space against other amyloid-targeting approaches, anti-tau therapies, and combination strategies. Key competitors include companies pursuing similar mechanisms (Eli Lilly, Biogen) and those using alternative approaches (Novartis, Roche). Alzheon's differentiation rests on its focus on amyloid oligomers and precision medicine targeting APOE4 carriers.
Industry Context
Alzheon, Inc. operates in Biopharmaceuticals - Neurodegenerative Diseases.
Key facts
Founded: 2013 · Headquarters: Framingham, Massachusetts, USA · Employees: 31 · Revenue: $6.3 million